1

Astellas Pharma

Astellas Pharma
Leadership team

Mr. Naoki Okamura BSc (Exec. VP, Chief Strategy Officer & Representative Director)

Minoru Kikuoka (CFO & Sr. Managing Exec. Officer)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
1,000 - 20,000
Headquarters
Tokyo, Tokyo, Japan
Established
2005
Company Registration
SEC CIK number: 0001446390
Net Income
1B - 20B
Revenue
Above - 1B
Traded as
TYO:4503
Overview
Location
Summary

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

History

Fujisawa Shoten was started in 1894 by Tomokichi Fujisawa in Osaka, and was renamed Fujisawa Pharmaceutical Co. in 1943. Yamanouchi Yakuhin Shokai was started in 1923 by Kenji Yamanouchi in Osaka. The company was renamed Yamanouchi Pharmaceutical Co. in 1940 and moved to Tokyo in 1942. Both companies started their overseas expansion at about the same time, opening offices in Taiwan in 1962 and 1963, respectively, and in the United States and Europe from 1977 onwards.

Fujisawa acquired Lyphomed in 1990 and thereafter established its US R&D center in Deerfield, Illinois. Yamanouchi's R&D center in Leiderdorp was established with the acquisition of the pharmaceutical division of Royal Gist Brocades in 1991. Fujisawa and Yamanouchi combined in a "merger of equals," forming Astellas Pharma on 1 April 2005. At least some of its older products continue to be distributed under the original brand, ostensibly due to high brand-name recognition. Astellas had a collaboration agreement with CoMentis from 2008 to 2014 focused on development of beta-secretase inhibitor therapeutics for Alzheimer's disease.In 2009, the company's tacrolimus-containing products Prograf and Advagraf showed they were prone to dosing errors within Europe, leading to serious adverse reactions among a number of patients, due to deficits in packaging and labeling, deficits corrected after a warning from the UK MHRA.On June 9, 2010, Astellas acquired OSI Pharmaceuticals for $4.0 billion. In December 2014, Astellas expanded its 18-month-old collaboration with Cytokinetics, focusing on the R&D and commercialization of skeletal muscle activators. The companies announced they will advance the development of CK-2127107 into Phase II clinical trials for the treatment of spinal muscular atrophy and possibly other neuromuscular conditions. The collaboration was expected to generate more than $600 million for Cytokinetics, as well as $75 million in milestone payments. In November 2015, the company announced its move to acquire Ocata Therapeutics for $379 million. The deal was completed in February 2016. Later in November 2015 the company announced it would sell its dermatology business to LEO Pharma for $725 million. In October 2016 Astellas announced it would acquire Ganymed Pharmaceuticals for $1.4 billionIn April 2017, the company announced it would acquire Belgium-based drug discovery firm Ogeda for up to a total €800 million, strengthening its late-stage pipeline with Ogeda's drug candidate, fezolinetant. In November 2017, the company announced that it exercised an option to purchase Cambridge, Massachusetts-based Mitobridge, which is developing treatments for Duchenne muscular dystrophy and age-related diseases.In August 2018, Astellas announced it would acquire Quethera Limited for $109 million. In December 2018, the company announced it would acquire Potenza Therapeutics, Inc.In December 2019, Astellas Pharma announced it would buy Audentes Therapeutics Inc for approximately $3 billion in cash as well as acquiring Xyphos Biosciences, Inc later in the same month. Audentes will operate as a wholly owned subsidiary within Astellas, and will serve as the Center of Excellence for the newly created Genetic Regulation Primary Focus, providing leadership for AAV pipeline advancement through commercialization, manufacturing expansion, and next-generation research initiatives. The acquisition includes Astellas gaining Xyphos’ Advanced Cellular Control through Engineered Ligands technology platform.Astellas Pharma's Smyraf obtained regulatory approval for the treatment of rheumatoid arthritis, the third oral Janus kinase inhibitor to receive approval.In October 2020, Astellas announced it would acquire iota Biosciences, Inc. for $127.5 million, with shareholders eligible to receive up to a further $176.5 million upon the achievement of predetermined milestones.

The following is an illustration of the company's major mergers and acquisitions and historical predecessors :

Mission

Sustainable enhancement of enterprise valueAstellas will seek to enhance its enterprise value in a sustainable manner.Astellas will seek to be the company of choice among all its stakeholders, including its customers, shareholders, employees, and the global community.Astellas will strive to gain the trust of all stakeholders and thereby enhance its enterprise value.

Vision

On the forefront of healthcare change to turn innovative science into value for patients

Key Team

Nobue Yasuda (Gen. Mang. of Fin. & Accounting Department)

Mr. Yoshitsugu Shitaka Ph.D. (Chief Scientific Officer & Sr. Managing Exec. Officer)

Ms. Catherine B. Levitt (Gen. Counsel)

Mr. Katsuyoshi Sugita (Chief People Officer and Chief Ethics & Compliance Officer)

Mr. Stig Ogata (VP of Corp. Communications)

Ms. Collette Taylor (Sr. VP of HR)

Chihiro Yokota (Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel.)

References
Astellas Pharma
Leadership team

Mr. Naoki Okamura BSc (Exec. VP, Chief Strategy Officer & Representative Director)

Minoru Kikuoka (CFO & Sr. Managing Exec. Officer)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
1,000 - 20,000
Headquarters
Tokyo, Tokyo, Japan
Established
2005
Company Registration
SEC CIK number: 0001446390
Net Income
1B - 20B
Revenue
Above - 1B
Traded as
TYO:4503